Inhibrx (INBX) Stock Price, News & Analysis

Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $12.25 to $14.77
• 50-Day Range: $13.83 to $17.49
• 52-Week Range: $10.80 to $18.95
• Volume: 178,264 shs
• Average Volume: 51,015 shs
• Market Capitalization: $200.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Hold

Inhibrx Stock Analysis - MarketRank™

Inhibrx scored higher than 79% of companies evaluated by MarketBeat, and ranked 255th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Inhibrx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Inhibrx has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inhibrx are expected to decrease in the coming year, from $87.50 to ($13.44) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.70% of the float of Inhibrx has been sold short.

Short Interest Ratio / Days to Cover

Inhibrx has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Inhibrx has recently increased by 9.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibrx does not currently pay a dividend.

Dividend Growth

Inhibrx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.21

Percentage of Shares Shorted

9.70% of the float of Inhibrx has been sold short.

Short Interest Ratio / Days to Cover

Inhibrx has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Inhibrx has recently increased by 9.04%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.05

News Sentiment

Inhibrx has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Inhibrx this week, compared to 1 article on an average week.

MarketBeat Follows

10 people have added Inhibrx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Inhibrx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,630,337.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INBX Stock Analysis - Frequently Asked Questions

How have INBX shares performed this year?

Inhibrx's stock was trading at $38.00 on January 1st, 2024. Since then, INBX stock has decreased by 63.6% and is now trading at $13.83.
View the best growth stocks for 2024 here.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) issued its quarterly earnings data on Tuesday, August, 13th. The company reported $125.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.60) by $129.08. The firm had revenue of $0.10 million for the quarter.

When did Inhibrx IPO?

Inhibrx (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Video Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INBX
• CUSIP: N/A
• CIK: 1739614
• Web: www.inhibrx.com
• Phone: 858-795-4220
• Fax: N/A
• Employees: 166
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $27.00
• High Stock Price Target: $27.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +95.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.20
• Quick Ratio: 6.20

Sales & Book Value

• Annual Sales: $1.63 million
• Price / Sales: 122.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,480,000
• Free Float: 11,262,000
• Market Cap: $200.26 million
• Optionable: Optionable
• Beta: N/A